Last reviewed · How we verify

Pharmaceutical Project Solutions, Inc. — Portfolio Competitive Intelligence Brief

Pharmaceutical Project Solutions, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RX0041 4% RX0041 4% phase 3 SSRI 5-HT receptor Psychiatry
RX0041 8% RX0041 8% phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. EMS · 2 shared drug classes
  2. Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 2 shared drug classes
  3. Astellas Pharma Inc · 2 shared drug classes
  4. Beni-Suef University · 2 shared drug classes
  5. PMG Pharm Co., Ltd · 2 shared drug classes
  6. Sun Pharmaceutical Industries Limited · 2 shared drug classes
  7. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  8. AceLink Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pharmaceutical Project Solutions, Inc.:

Cite this brief

Drug Landscape (2026). Pharmaceutical Project Solutions, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmaceutical-project-solutions-inc. Accessed 2026-06-10.

Related